FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGE</b>	S IN BENEFIC	CIAL OWNERS	HIP

l	OIVIB APPROVAL									
l	OMB Number:	3235-0287								
l	Estimated average burden									
l	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							_										
1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Aviragen Therapeutics, Inc. [ AVIR ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
COLONNESE MARK P			-	Tivingen Therapeaces, Inc. [ Tivin ]								Director			10% Ow		
(Last)	(1	Tiret)	(Middle)		Date of Earliest Transaction (Month/Day/Year)								X Officer ( below)	give title		Other (sp below)	ecify
				0	07/27/2016								CFO and EVP				
2500 NORTHWINDS PARKWAY, SUITE 100																	
(Street)				— <b>[</b> 4	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
ALPHAI	RETTA C	A	30009										X Form fil	ed by One F	Report	ing Person	
												Form filed by More than One Reporting Person				ng	
(City)	(9	State)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
								<del>'</del>		•						[_	
1. Title of S	Security (Ins	tr. 3)	Da		Execution Date							and 5) Securities		Form: Direct Ir		. Nature of ndirect	
(Month/l			(M	Month/Day/Year)		if any (Month/Day/Yea		Code (Instr.					Beneficial Owned Fo		(D) or I: (I) (Inst		Beneficial Ownership
										Amount (A)			Reported Transaction	on(s)		· [	(Instr. 4)
							Code	V	Amount	nount (A) or Pr			nstr. 3 and 4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																
										onvertil							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
						1			$\top$			Amount		(Instr. 4)	(3)		
				Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	or Number of Shares					
Stock Option (Right to Buy)	\$1.34	07/27/2016		A		150,000		07/27/201	7(1)	07/27/2026	Common Stock	150,000	\$1.34	375,000	0	D	

## **Explanation of Responses:**

1. The stock option vests in equal annual installments beginning on the first anniversary and thereafter on the second and third anniversary ratably.

/s/ Mark P. Colonnese

07/29/2016

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.